ACAD vs PFE · P/E 15, rev $576.0M vs P/E 20, rev $15.03B
ACADIA Pharmaceuticals Inc (ACAD) versus Pfizer Inc (PFE) — a side-by-side from cached financials, not a winner call.
ACADIA Pharmaceuticals Inc (ACAD) is a biotechnology company listed on US.
Pfizer Inc (PFE) is a drug manufacturers - general company listed on NYSE. It is led by Albert Bourla.
Latest reported ACAD revenue for 2026-06-30 was $576.0M. Net income was $35.1M. ACAD currently screens at market cap $3.51B and trailing P/E 15.3.
Latest reported PFE revenue for 2026-06-28 was $15.03B. Net income was -$248.0M. Revenue was up 4.0% from 2026-03-29 to 2026-06-28. PFE currently screens at market cap $147.73B and trailing P/E 19.8.
ACAD currently screens at market cap $3.51B and trailing P/E 15.3. PFE currently screens at market cap $147.73B and trailing P/E 19.8.
Not investment advice. Open the ACAD and PFE stock pages for the full models.
Not investment advice.